Influence of Transfusion Recipient and Donor Traits in Patients with Sickle Cell Disease Many patients with sickle cell disease (SCD) receive chronic RBC transfusions to ensure non-sickled erythrocytes are in circulation. In 20-30%… June 3, 2026
Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease β-thalassemia and sickle cell disease (SCD) are the most common monogenic diseases worldwide. About 20% of these patients may be… April 28, 2026
Storage Duration Affects Hematological and Metabolic Parameters in Patients with Sickle Cell Disease Red blood cells (RBCs) may be stored for up to 42 days before transfusion; however, over time they may develop… July 16, 2025
Sickle Cell Trait Testing of RBC Units While individuals with the sickle cell trait (SCT) have a single allele of hemoglobin S (HbS) and are eligible blood… December 27, 2022
HbS Promotes Proinflammatory Cytokine Production in Sickle Cell Disease Unlike patients with intravascular hemolysis without sickle cell disease (SCD) or those with β-thalassemia, patients with SCD have elevated baseline… November 9, 2022
LentiGlobin Therapy for Sickle Cell Disease Sickle cell disease (SCD) is caused by a single point mutation in the β-globin gene and affects around 100,000 people… January 4, 2022
Cost-Effectiveness of Transfusions to Prevent Silent Cerebral Infarcts in Children with Sickle Cell Disease Guidelines published by the American Society of Hematology in 2020 recommend annual transcranial doppler ultrasound (TCD) screening to help identify… December 29, 2021
Reducing Red Cell Use for Patients with Sickle Cell Disease during a Pandemic Since March 2020, the COVID-19 pandemic has strained blood inventories, so researchers at one Philadelphia hospital implemented new measures to… June 30, 2021
T helper Cells and Alloimmunization in Patients with Sickle Cell Disease Alloimmunization can lead to life-threatening hemolytic transfusion reactions and make it difficult to find compatible blood. While it is unknown… March 16, 2021
Experimental Drug Voxelotor for Treatment of Patients with Sickle Cell Disease Results from a multicenter, randomized, clinical trial suggests that voxelotor, which inhibits sickle hemoglobin (HbS) polymerization, may be beneficial for… July 3, 2019
